We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far?
- Authors
Psilopatis, Iason; Damaskos, Christos; Garmpi, Anna; Sarantis, Panagiotis; Koustas, Evangelos; Antoniou, Efstathios A.; Dimitroulis, Dimitrios; Kouraklis, Gregory; Karamouzis, Michail V.; Vrettou, Kleio; Marinos, Georgios; Kontzoglou, Konstantinos; Garmpis, Nikolaos
- Abstract
Unresectable hepatocellular carcinoma (HCC) is an advanced primary liver malignancy with a poor prognosis. The Food and Drug Administration (FDA) has, to date, approved nivolumab, pembrolizumab, ramucirumab, nivolumab/ipilimumab, atezolizumab/bevacizumab, as well as tremelimumab/durvalumab, as first- or second-line monoclonal antibodies (mAbs) for unresectable HCC. The present review examines the current state of knowledge, and provides a useful update on the safety and efficacy of these therapeutic agents, thus attempting to define the suitability of each mAb for different patient subgroups.
- Subjects
UNITED States. Food &; Drug Administration; HEPATOCELLULAR carcinoma; ATEZOLIZUMAB; NIVOLUMAB; TREATMENT effectiveness; IPILIMUMAB; MONOCLONAL antibodies
- Publication
International Journal of Molecular Sciences, 2023, Vol 24, Issue 3, p2685
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms24032685